The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated with Persistent Infections and Adverse Outcomes Independent from Its Multidrug Resistance and Associations with Compromised Hosts

Clinical Infectious Diseases

Volumn 62, Issue 12, 2016, Pages 1529-1536

  Johnson, James R ^a,b   Thuras, Paul ^a,b   Johnston, Brian D ^a,b   Weissman, Scott J ^c,d   Limaye, Ajit P ^c   Riddell, Kim ^e   Scholes, Delia ^c,e   Tchesnokova, Veronika ^c   Sokurenko, Evgeni ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

antimicrobial resistance; Escherichia coli infections; host compromise; long term care; ST131

Indexed keywords

CARBAPENEM; CEPHALOSPORIN; COTRIMOXAZOLE; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CLINICAL FEATURE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI ST131 H30; FEMALE; GENOTYPE; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULAR CLONING; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NEWBORN; NONHUMAN; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973441003     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw193     Document Type: Article

References (35)

1. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: An overlooked epidemic. Microbes Infect 2003; 5:449-56.
2. Ironmonger D, Edeghere O, Bains A, Loy R, Woodford N, Kawkey PM. Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. J Antimicrob Chemother 2015; 70:1744-50.
3. Wong PH, von Krosigk M, Roscoe DL, Lau TT, Yousefi M, Bowie WR. Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: A longitudinal epidemiological study from 2002-2011. BMC Infect Dis 2014; 14:393.
4. Bitsori M, Maraki S, Galanakis E. Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis. Pediatr Nephrol 2014; 29:1053-8.
5. Lagacé-Wiens PR, Adam HJ, Low DE, et al. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother 2013; 68(suppl 1):i23-9.
6. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 2008; 8:159-66.
7. Sanchez GV, Adams SJ, Baird AM, Master RN, Clark RB, Bordon JM. Escherichia coli antimicrobial resistance increased faster among geriatric outpatients compared with adult outpatients in the USA, 2000-10. J Antimicrob Chemother 2013; 68:1838-41.
8. Nicolas-Chanoine M, Bertrand X, Madec J-Y. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27:543-74.
9. Johnson JR, Tchesnokova V, Johnston B, et al. Abrupt emergence of a single dominant multi-drug-resistant strain of Escherichia coli. J Infect Dis 2013; 207:919-28.
10. Price LB, Johnson JR, Aziz M, et al. The epidemic of ESBL-producing Escherichia coli ST131 is driven by a single highly virulent subclone, H30-Rx. mBio 2013; 6: e00377-13.
11. Petty NK, Ben Zakour N, Stanton-Cook M, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 2014; 111:5694-9.
12. Colpan A, Johnston B, Porter S, et al. Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans. Clin Infect Dis 2013; 57:1256-65.
13. Peirano G, Pitout JDD. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother 2014; 58:2600-703.
14. Peirano G, van der Bij AK, Freeman JL, et al. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum beta-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother 2014; 58:3762-7.
15. Vimont S, Boyd A, Bleibtreu A, et al. The CTX-M-15-producing Escherichia coli clone O25b:H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012; 7:e46547.
16. Clermont O, Lavollay M, Vimont S, et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61:1024-8.
17. Tchesnokova V, Billig M, Chattopadhyay S, et al. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol 2013; 51:2991-9.
18. Ciesielczuk H, Betts J, Phee L, et al. Comparative virulence of urinary and bloodstream isolates of extra-intestinal pathogenic Escherichia coli in a Galleria mellonella model. Virulence 2015; 6:145-51.
19. Lavigne JP, Vergunst AC, Goret L, et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 2012; 7: e34294.
20. Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012; 80:1554-62.
21. Johnson JR, Johnston B, Kuskowski MA, Sokurenko EV, Tchesnokova V. Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 vs. other fluoroquinolone-resistant E. coli. Antimicrob Agents Chemother 2015; 59:4471-80.
22. Johnson JR, Porter SB, Thuras P, et al. Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131. Antimicrob Agents Chemother 2015; 59: 7132-5.
23. Burgess MJ, Johnson JR, Porter SB, et al. Long term care facilities as reservoirs for antimicrobial-resistant sequence type 131 Escherichia coli. Open Forum Infect Dis 2015; 2:ofv011.
24. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type ST131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013; 34:361-9.
25. Ludden C, Cormican M, Vellinga A, Johnson JR, Austin B, Morris D. Colonisation with ESBL-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant enterococci, and meticillin-resistant Staphylococcus aureus in a long-term care facility over one year. BioMed Central 2015; 15:168.
26. López-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014; 69:809-14.
27. Olesen B, Hansen DS, Nilsson F, et al. Prevalence and characteristics of the epidemic multi-resistant Escherichia coli ST131 clonal group among extendedspectrum β-lactamase (ESBL)-producing E. coli in Copenhagen. J Clin Microbiol 2013; 51:1779-85.
28. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-55.
29. Dhanji H, Doumith M, Rooney PJ, et al. Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum betalactamases in nursing homes in Belfast, UK. J Antimicrob Chemother 2011; 66:297-303.
30. Johnson JR, Moseley S, Roberts P, Stamm WE. Aerobactin and other virulence factor genes among strains of Escherichia coli causing urosepsis: Association with patient characteristics. Infect Immun 1988; 56:405-12.
31. Johnson JR, Porter S, Johnston B, et al. Host characteristics and bacterial traits predict experimental virulence for Escherichia coli bloodstream isolates from patients with urosepsis. Open Forum Infect Dis 2015; 2:ofv083.
32. Rooney PJ, O'Leary MD, Loughrey AC, et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009; 64:635-41.
33. Can F, Azap OK, Seref C, Ispir P, Arslan H, Ergonul O. Emerging Escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections. Clin Infect Dis 2015; 60:523-7.
34. Ezeh AC, Bongaarts J, Mberu B. Global population trends and policy options. Lancet 2012; 380:142-8.
35. Faden HS, Ma CX. Trends in oral antibiotic, proton pump inhibitor, and histamine 2 receptor blocker prescription patterns for children compared with adults: implications for Clostridium difficile infection in the community. Clin Pediatr (Phila) 2015:pii:0009922815604596.